A culturally-tailored behavioral intervention trial for alcohol use disorders in three American Indian communities: Rationale, d
Authors:
Journal: Contemporary clinical trials
Publication Type: Journal Article
Date: 2016
DOI: NIHMS762798
ID: 26706667
Abstract
Disproportionately high rates of alcohol use disorders are present in many American Indian/Alaska Native (AI/AN) communities, yet little information exists regarding the effectiveness of alcohol treatments in AI/AN populations. Contingency management is an intervention for illicit drug use in which tangible reinforcers (rewards) are provided when patients demonstrate abstinence as assessed by urine drug tests. Contingency management has not been widely studied as an intervention for alcohol problems because until recently, no alcohol biomarker has been available to adequately verify abstinence.
Chemical List
- Glucuronates|||ethyl glucuronide
Reference List
- SAMHSA . The NSDUH report: substance use and substance use disorders among American Indians and Alaska Natives. Substance Abuse and Mental Health Services Administration, Office of Applied Studies; Rockville, MD: Jan 19, 2007. 2007.|||Evans E, Spear SE, Huang Y-C, Hser Y-I. Outcomes of drug and alcohol treatment programs among American Indians in California. Am. J. Public Health. 2006;96(5):889–896. (%U http://ajph.aphapublications.org/cgi/content/abstract/896/885/889/)|||Feldstein SW, Venner KL, May PA. American Indian/Alaska Native alcohol-related incarceration and treatment. Am. Indian Alsk. Native Ment. Health Res. (Online) 2006;13(3):1–22.|||Callaghan RC. Risk factors associated with dropout and readmission among First Nations individuals admitted to an inpatient alcohol and drug detoxification program. CMAJ. 2003;169(1):23–27.|||Naimi TS, Cobb N, Boyd D, Jarman DW, Espey D, Snesrud P, Chavez P. Alcohol-attributable deaths and years of potential life lost among American Indians and Alaska Natives — United States, 2001–2005. MMWR. 2008;57(34):938–941.|||Boyd-Ball AJ. A culturally responsive, family-enhanced intervention model. Alcohol. Clin. Exp. Res. 2003;27(8):1356–1360.|||Gossage JP, Barton L, Foster L, Etsitty L, LoneTree C, Leonard C, May PA. Sweat lodge ceremonies for jail-based treatment. J. Psychoactive Drugs. 2003;35(1):33–42.|||Allen J, Mohatt GV, Rasmus SM, Hazel KL, Thomas L, Lindley S. The tools to understand: community as co-researcher on culture-specific protective factors for Alaska Natives. J. Prev. Interv. Community. 2006;32(1–2):41–59.|||Ringwalt C, Bliss K. The cultural tailoring of a substance use prevention curriculum for American Indian youth. J. Drug Educ. 2006;36(2):159–177.|||O'Malley SS, Robin RW, Levenson AL, GreyWolf I, Chance LE, Hodgkinson CA, Romano D, Robinson J, Meandzija B, Stillner V, Wu R, Goldman D. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol. Clin. Exp. Res. 2008;32(7):1271–1283.|||Woodall WG, Delaney HD, Kunitz SJ, Westerberg VS, Zhao H. A randomized trial of a DWI intervention program for first offenders: intervention outcomes and interactions with antisocial personality disorder among a primarily American-Indian sample. Alcohol. Clin. Exp. Res. 2007;31(6):974–987.|||Montag AC, Brodine SK, Alcaraz JE, Clapp JD, Allison MA, Calac DJ, Hull AD, Gorman JR, Jones KL, Chambers CD. Preventing alcohol-exposed pregnancy among an American Indian/Alaska Native population: effect of a screening, brief intervention, and referral to treatment intervention. Alcohol. Clin. Exp. Res. 2015;39(1):126–135.|||Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction. 2006;101(2):192–203.|||Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006;101(11):1546–1560.|||Olmstead TA, Petry NM. The cost-effectiveness of prize-based and voucher-based contingency management in a population of cocaine- or opioid-dependent outpatients. Drug Alcohol Depend. 2009;102(1–3):108–115.|||Murphy SM, McDonell MG, McPherson S, Srebnik D, Angelo F, Roll JM, Ries RK. An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness. Drug Alcohol Depend. (In Press)|||Rawson RA, McCann MJ, Flammino F, Shoptaw S, Miotto K, Reiber C, Ling W. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction (Abingdon) 2006;101(2):267–274.|||Montgomery L, Petry NM, Carroll KM. Moderating effects of race in clinical trial participation and outcomes among marijuana-dependent young adults. Drug Alcohol Depend. 2012;126(3):333–339.|||Barry D, Sullivan B, Petry NM. Comparable efficacy of contingency management for cocaine dependence among African American, Hispanic, and white methadone maintenance clients. Psychol. Addict. Behav. 2009;23(1):168–174.|||Bride BE, Humble MN. Increasing retention of African-American women on welfare in outpatient substance user treatment using low-magnitude incentives. Subst. Use Misuse. 2008;43(8–9):1016–1026.|||Hser YI, Li J, Jiang H, Zhang R, Du J, Zhang C, Zhang B, Evans E, Wu F, Chang YJ, Peng C, Huang D, Stitzer ML, Roll J, Zhao M. Effects of a randomized contingency management intervention on opiate abstinence and retention in methadone maintenance treatment in China. Addiction. 2011;106(10):1801–1809.|||Wurst FM, Kempter C, Metzger J, Seidl S, Alt A. Ethyl glucuronide: a marker of recent alcohol consumption with clinical and forensic implications. Alcohol. 2000;20(2):111–116.|||Wurst FM, Kempter C, Seidl S, Alt A. Ethyl glucuronide—a marker of alcohol consumption and a relapse marker with clinical and forensic implications. Alcohol Alcohol. 1999;34(1):71–77.|||Wurst FM, Seidl S, Ladewig D, Muller-Spahn F, Alt A. Ethyl glucuronide: on the time course of excretion in urine during detoxification. Addict. Biol. 2002;7(4):427–434.|||Wurst FM, Skipper GE, Weinmann W. Addiction. Vol. 98. Suppl. 2: 2003. Ethyl glucuronide—the direct ethanol metabolite on the threshold from science to routine use; pp. 51–61.|||Wurst FM, Tabakoff B, Alling C, Aradottir S, Wiesbeck GA, Muller-Spahn F, Pragst F, Johnson B, Javors M, Ait-Daoud N, Skipper GE, Spies C, Nachbar Y, Lesch O, Ramskogler K, Hartmann S, Wolfersdorf M, Dresen S, Weinmann W, Hines L, Kaiser A, Lu RB, Ko HC, Huang SY, Wang TJ, Wu YS, Whitfield J, Snell LD, Wu C, Hoffman PL. World Health Organization/International Society for Biomedical Research on Alcoholism study on state and trait markers of alcohol use and dependence: back to the future. Alcohol. Clin. Exp. Res. 2005;29(7):1268–1275.|||Wurst FM, Vogel R, Jachau K, Varga A, Alling C, Alt A, Skipper GE. Ethyl glucuronide discloses recent covert alcohol use not detected by standard testing in forensic psychiatric inpatients. Alcohol. Clin. Exp. Res. 2003;27(3):471–476.|||Skipper GE, Weinmann W, Thierauf A, Schaefer P, Wiesbeck G, Allen JP, Miller M, Wurst FM. Ethyl glucuronide: a biomarker to identify alcohol use by health professionals recovering from substance use disorders. Alcohol Alcohol. 2004;39(5):445–449.|||Helander A, Bottcher M, Fehr C, Dahmen N, Beck O. Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. Alcohol Alcohol. 2009;44(1):55–61.|||Kip MJ, Spies CD, Neumann T, Nachbar Y, Alling C, Aradottir S, Weinmann W, Wurst FM. The usefulness of direct ethanol metabolites in assessing alcohol intake in nonintoxicated male patients in an emergency room setting. Alcohol. Clin. Exp. Res. 2008;32(7):1284–1291.|||McDonell MG, Srebnik D, Angelo F, Sugar AM, Howell D, Rainey C, Roll J, Short R, Ries R. Evaluation of ethyl glucuronide immunoassay urinalysis in five alcohol-dependent outpatients. Am. J. Addict. 2011;20(5):482–484.|||Wurst FM, Metzger J. The ethanol conjugate ethyl glucuronide is a useful marker of recent alcohol consumption. Alcohol. Clin. Exp. Res. 2002;26(7):1114–1119.|||Litten RZ, Bradley AM, Moss HB. Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol. Clin. Exp. Res. 2010;34(6):955–967.|||Leickly E, McDonell M, Vilardaga R, Angelo F, Lowe J, McPherson S, Srebnik D, Roll J, Ries R. High levels of agreement between clinic-based ethyl glucuronide immunoassays and laboratory-based mass spectrometry. Am. J. Drug Alcohol Abuse. (In Press)|||Lowe J, McDonell M, Leickly E, Angelo F, Vilardaga R, McPherson S, Srebnik D, Roll J, Ries R. Determining ethyl glucuronide cutoffs when detecting self-reported alcohol use in addiction treatment patients. Alcohol. Clin. Exp. Res. (In Press)|||McDonell MG, Howell DN, McPherson S, Cameron JM, Srebnik D, Roll JM, Ries RK. Voucher-based reinforcement for alcohol abstinence using the ethyl-glucuronide alcohol biomarker. J. Appl. Behav. Anal. 2012;45(1):161–165.|||Association AP . DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. text revision ed. AMERICAN PSYCHIATRIC PRESS INC (DC); Washington, DC: 2000.|||Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry. 1998;59(Suppl. 20):22–33.|||Donlin WD, Knealing TW, Needham M, Wong CJ, Silverman K. Attendance rates in a workplace predict subsequent outcome of employment-based reinforcement of cocaine abstinence in methadone patients. J. Appl. Behav. Anal. 2008;41(4):499–516.|||Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 2009;42(2):377–381.|||Petry NM, Peirce JM, Stitzer ML, Blaine J, Roll JM, Cohen A, Obert J, Killeen T, Saladin ME, Cowell M, Kirby KC, Sterling R, Royer-Malvestuto C, Hamilton J, Booth RE, Macdonald M, Liebert M, Rader L, Burns R, DiMaria J, Copersino M, Stabile PQ, Kolodner K, Li R. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study. Arch. Gen. Psychiatry. 2005;62(10):1148–1156.|||Peirce JM, Petry NM, Stitzer ML, Blaine J, Kellogg S, Satterfield F, Schwartz M, Krasnansky J, Pencer E, Silva-Vazquez L, Kirby KC, Royer-Malvestuto C, Roll JM, Cohen A, Copersino ML, Kolodner K, Li R. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a national drug abuse treatment clinical trials network study. Arch. Gen. Psychiatry. 2006;63(2):201–208.|||Roll JM, Petry NM, Stitzer ML, Brecht ML, Peirce JM, McCann MJ, Blaine J, MacDonald M, DiMaria J, Lucero L, Kellogg S. Contingency management for the treatment of methamphetamine use disorders. Am. J. Psychiatry. 2006;163(11):1993–1999.|||Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, Stine S, Gonzalez G, Gonsai K. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend. 2003;70(3):315–325.|||Oliveto A, Poling J, Sevarino KA, Gonsai KR, McCance-Katz EF, Stine SM, Kosten TR. Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients. Drug Alcohol Depend. 2005;79(2):157–165.|||Carise D, Wicks K, McLellan AT, Olton P. Addiction Severity Index 5th Edition — North Dakota State Adaptation for Use With Native Americans. Treatment Research Institute at University of Pennsylvania; Philadelphia, PA: 1998.|||Sobell LC, Sobell MB. Alcohol timeline followback (TLFB), Handbook of Psychiatric Measures. American Psychiatric Association; Washington DC: 2000. pp. 477–479.|||Barry D, Weinstock J, Petry NM. Ethnic differences in HIV risk behaviors among methadone-maintained women receiving contingency management for cocaine use disorders. Drug Alcohol Depend. 2008;98(1–2):144–153.|||Darke S, Hall W, Heather N, Ward J, Wodak A. The reliability and validity of a scale to measure HIV risk-taking behaviour among intravenous drug users. AIDS. 1991;5(2):181–185.|||Ware J, Jr., Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med. Care. 1996;34(3):220–233.|||Quandt SA, Graham CN, Bell RA, Snively BM, Golden SL, Stafford JM, Arcury TA. Ethnic disparities in health-related quality of life among older rural adults with diabetes. Ethn. Dis. 2007;17(3):471–476.|||Miller WR, Tonigan JS. Assessing drinkers' motivation for change: the stages of change readiness and treatment eagerness scale (SOCRATES) Psychol. Addict. Behav. 1996;10(2):81–89.|||Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br. J. Addict. 1991;86(9):1119–1127.|||Grant T, Novick Brown N, Graham J, Whitney N, Dubovsky D, Nelson L. Screening in treatment programs for Fetal Alcohol Spectrum Disorders that could affect therapeutic progress. Int. J. Alcohol Drug Res. 2013;2(3):37–49.|||Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic. Dis. 1987;40(5):373–383.|||Jiang L, Beals J, Whitesell NR, Roubideaux Y, Manson SM, Team A-S. Stress burden and diabetes in two American Indian reservation communities. Diabetes Care. 2008;31(3):427–429.|||Winderowd C, Montgomery D, Stumblingbear G, Harless D, Hicks K. Development of the American Indian enculturation scale to assist counseling practice. Am. Indian Alsk. Native Ment. Health Res. 2008;15(2):1–14.|||Whitbeck LB, Adams GW, Hoyt DR, Chen X. Conceptualizing and measuring historical trauma among American Indian people. Am. J. Community Psychol. 2004;33(3–4):119–130.|||Whitbeck LB, Chen XJ, Hoyt DR, Adams GW. Discrimination, historical loss and enculturation: culturally specific risk and resiliency factors for alcohol abuse among American Indians. J. Stud. Alcohol. 2004;65(4):409–418.|||Gray S, Borgundvaag B, Sirvastava A, Randall I, Kahan M. Feasibility and reliability of the SHOT: a short scale for measuring pretreatment severity of alcohol withdrawal in the emergency department. Acad. Emerg. Med. 2010;17(10):1048–1054.|||Mcdonell M, Srebnik D, Angelo F, McPherson S, Lowe J, Sugar A, Short R, Roll J, Ries R. A randomized controlled trial of contingency management for psycho-stimulant use in community mental health outpatients with co-occurring serious mental illness. Am. J. Psychiatry. 2013;170:94–101.|||McPherson S, Barbosa-Leiker C, Burns GL, Howell D, Roll J. Missing data in substance abuse treatment research: current methods and modern approaches. Exp. Clin. Psychopharmacol. 2012|||Silverman K, Wong CJ, Needham M, Diemer KN, Knealing T, Crone-Todd D, Fingerhood M, Nuzzo P, Kolodner K. A randomized trial of employment-based reinforcement of cocaine abstinence in injection drug users. J. Appl. Behav. Anal. 2007;40(3):387–410.|||Higgins ST, Delaney DD, Budney AJ, Bickel WK, Hughes JR, Foerg F, Fenwick JW. A behavioral approach to achieving initial cocaine abstinence. Am. J. Psychiatry. 1991;148(9):1218–1224.|||Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badger GJ. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch. Gen. Psychiatry. 1994;51(7):568–576.|||Enders CK. Applied Missing Data Analysis. Guilford Press; New York: 2010.